Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Inhalation to Prevent ARDS in COVID-19 Pneumonia (GI-COVID)

NCT04569877 is registered in ClinicalTrials.gov with University of Giessen as lead sponsor.

NCT NCT04569877
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04569877 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Inhalation to Prevent ARDS in COVID-19 Pneumonia (GI-COVID)
Lead sponsor
University of Giessen
Phase
Phase 2
Overall status
Completed
Start date
September 24, 2020
Completion date
September 20, 2022
Enrollment
63 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19 pneumonia, severe acute respiratory syndrome (sars) pneumonia